Model predicts combo therapy may cure hepatitis C in 2 months
New modeling data predict that bemnifosbuvir and ruzasvir, an experimental combination treatment being developed by Atea Pharmaceuticals for chronic hepatitis C, may…
Marisa Wexler, MS, Senior Science Writer—
Articles by Marisa Wexler
Melatonin may protect the liver from cholestasis-related injury
Treatment with melatonin, a naturally occurring hormone best known for regulating sleep, may help reduce liver injury caused by cholestasis, according to a study…
Rezdiffra reduces liver scarring in high-risk MASH patients: Trial data
Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring and other signs of advanced disease in adults with high-risk compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis…
New drug HU6 cuts liver fat but preserves muscle mass
HU6, an experimental oral therapy from Rivus Pharmaceuticals, safely and effectively reduced liver fat and led to fat-selective weight loss in adults with metabolic…
All spots filled in trial testing Vir’s combo treatment for hepatitis D
Enrollment is now complete for Vir Biotechnology’s global ECLIPSE 1 trial, which is testing the combination treatment of tobevibart and elebsiran in people with chronic…
Emerging forever chemical may drive fatty liver disease
Exposure to a human-made chemical called perfluoroheptanoic acid (PFHpA) may increase the risk and severity of fatty liver disease in adolescents with obesity, according…
Hepatitis D therapy RBD1016 wins orphan drug designation in EU
The European Medicines Agency (EMA) has granted orphan drug designation to Suzhou Ribo Life Science’s experimental therapy RBD1016 for hepatitis D. The EMA gives…
This year, it’s ‘hope into action’ for PSC Awareness Day
Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…
Long-term ketogenic diet may cause fatty liver disease, per mouse study
A long-term ketogenic diet, which favors fats over carbs, may promote weight loss, but it can also cause fatty liver disease and blood sugar…
Potential biliary atresia treatment AX-0810 to enter clinical testing
AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…